

Date of Deposit: November 4, 1999

PATENTAttorney's Ref. No. 245-53722

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box PATENT APPLICATION
 ASSISTANT COMMISSIONER FOR PATENTS
 Washington, D.C. 20231

Transmitted herewith for filing is the patent application of:

Inventor(s): Walt Ream, Machteld Mok, and Hyewon Lee

For: PLANTS HAVING ENHANCED GALL RESISTANCE AND METHODS AND
 COMPOSITIONS FOR PRODUCING SAME

Enclosed are:

- ☒ 31 pages of specification, 4 pages of claims, an abstract and a Combined Declaration and Power of Attorney.
- ☒ 5 sheet(s) of informal drawings.
- ☒ Verified Statement(s) (Declaration) Claiming Small Entity Status:
- ☐ Independent Inventor (37 CFR §§ 1.9(f) and 1.27(b)).
- ☒ Small Business Concern (37 CFR §§ 1.9(f) and 1.27(c)).
- ☐ Nonprofit Organization (37 CFR §§ 1.9(f) and 1.27(d)).
- ☐ Non-Inventor Supporting a Claim by Another for Small Entity Status (37 CFR §§ 1.9(c) and 1.27(b)).
- ☒ Nucleotide and/or Amino Acid Sequence Submission
- ☒ Electronic Format, on computer disk
- ☒ Paper Copy (identical to computer copy), 5 pages
- ☒ Statement in compliance with 37 C.F.R. § 1.821 verifying identity of above copies

FILING FEE

For	Claims Filed	Number Free	Number Extra	Rate	Basic Fee
Total Claims	28	20	= 8	\$18.00	\$ 144.00
Independent Claims	5	3	= 2	\$78.00	\$ 156.00
Multiple Dependent Claim Fee				\$260.00	
TOTAL FILING FEE					\$1060.00

- ☒ A check in the amount of \$1,060.00 to cover ☒ filing fee and ☐ assignment recordal fee is enclosed.

Date of Deposit: November 4, 1999

PATENT


Attorney's Ref. No. 245-53722

- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this application and recording any assignment filed herewith, or credit over-payment, to Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL
LEIGH & WHINSTON, LLP

By


Paula A. DeGrandis
Registration No. 43,581

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Client
Docketing Secretary

PLANTS HAVING ENHANCED GALL RESISTANCE AND METHODS AND COMPOSITIONS FOR PRODUCING SAME

CROSS REFERENCE TO RELATED CASES

- 5 This application claims priority from a co-pending U.S. Provisional Application No. 60/107,185, filed November 5, 1998, which is incorporated herein by reference.

FIELD OF THE INVENTION

- 10 This invention is directed generally to compositions and methods for producing plants resistant to gall disease. The methods involve transforming plants with nucleic acid constructs encoding sense-strand untranslatable RNA molecules and/or double-stranded RNA molecules, RNA molecules that are similar to (but not identical to) certain *Agrobacterium* tumor-inducing genes.

15

BACKGROUND OF THE INVENTION

- Several different recombinant DNA technologies have been employed to interfere with gene expression in plants including technologies based on ribozyme molecules, antisense RNA molecules, and co-suppression constructs. For a general
20 discussion of ribozyme technology, antisense technology and co-suppression technology, see Castanotto, *Crit. Rev. Eukaryot. Gen. Expr.* 2:331-357, 1997; Simons, *Gene*, 72:35-44, 1988; and Jorgensen, *Biotechnol.* 8:340-344, 1990, respectively.

- In addition to standard co-suppression techniques, researchers have studied
25 the suppression of a target gene caused by the introduction of an untranslatable sense-strand transgene. (Dougherty and Parks, *Curr. Opin. Cell Biol.* 7:399-405, 1995; Jorgensen et al., *Science*, 279:1486-1487, 1998). This method has been used to silence a number of endogenous plant genes, as well as viral genes. (Marano and Baulcombe, *Plant J.* 13:537-546, 1998; Conner et al., *Plant J.* 11:809-823, 1997,
30 Dougherty et al., *Mol. Plant-Microbe Interact.* 7:544-552, 1994; and Smith et al., *Plant Cell* 6:1441-1453, 1994).

60434837.110499

The bacterial genus *Agrobacterium* contains several species that cause disease in economically important plants. For example, *Agrobacterium tumefaciens* causes gall tumors when it infects the wounded tissue of certain dicotyledonous plants such as apple trees and grape vines (DeCleene and DeLey, *Bot. Rev.* **42**:389-466, 1976). Pathogenic strains of *Agrobacterium* harbor a tumor-inducing (Ti) plasmid that carries genes essential for gall tumorigenesis (Watson et al., *J. Bacteriol.* **123**:255-264, 1975; Van Larebeke et al., *Nature* **252**:169-170, 1974).

The transferred DNA ("T-DNA"; **Figure 1**) portion of the Ti plasmid enters the cells of susceptible plants and integrates into nuclear DNA (Chilton et al., *Cell* **11**:263-271, 1977; Willmitzer et al., *Nature* **287**:359-361, 1980; Chilton et al., *Proc. Natl. Acad. Sci. USA* **77**:4060-4064, 1980). Following T-DNA integration in cellular DNA, expression of three T-DNA genes, *iaaM*, *iaaH*, and *ipt*, leads to overproduction of the plant growth hormones auxin and cytokinin, resulting in tumorous growths referred to as "galls." (Ream, *Annual Rev. Phytopathol.* **27**:583-618, 1989; Winans, *Micro. Revs.* **56**:12-31, 1992; and Zambryski, *Annu. Rev. Plant Physiol. Plant Mol. Biol.* **43**:465-490, 1992) (**Figure 2**). The *iaaM*, *iaaH*, and *ipt* genes have been well characterized, and the sequences of these genes are available for example in the Genbank database under accession numbers X56185, M25805, and X17428, respectively.

iaaM and *iaaH* are required for auxin production: the enzyme encoded by *iaaM* converts tryptophan into indole acetamide, which the enzyme encoded by *iaaH* converts into indole acetic acid, an auxin (Schroeder et al., *Eur. J. Biochem.* **138**:387-391, 1984; Thomashow et al., *Proc. Natl. Acad. Sci.* **81**:5071-5075, 1985; Thomashow et al., *Science* **231**:616-618, 1986; and Inze et al., *Mol. Gen. Genet.* **194**:265-274, 1984). Loss of either enzyme prevents auxin production. *ipt* is required for cytokinin production; the enzyme encoded by this gene converts adenosine monophosphate into isopentenyl adenosine monophosphate, a cytokinin (Akiyoshi et al. *Proc. Natl. Acad. Sci. USA* **81**:5994-5998, 1984; Barry et al., *Proc. Natl. Acad. Sci. USA* **81**:4776-4780, 1984; and Buchmann et al., *EMBO J.* **4**:853-859, 1985). Inactivation of *ipt* and either one of the two auxin-biosynthesis genes on

09434837-110499

the Ti plasmid will reduce gall formation (Ream et al., *Proc. Natl. Acad. Sci. USA* 80:1660-1664, 1983).

Additionally, galls can be formed in cases in which just the cytokinin pathway, or only the auxin biosynthesis pathway, is functional. In these cases the galls are visually distinguishable based on their different morphological characteristics. For example, plants infected with an *Agrobacterium* strain that carries only the gene necessary for the production of auxin develop necrotic galls. In contrast, plants infected with strains of the bacteria that induce only the production of cytokinin produce shooty galls.

To date, adequate means do not exist to control gall disease on grape vines, fruit trees, nut trees, chrysanthemums, roses, cane berries, ornamental shrubs, and other nursery crops. Inoculation of plants with *Agrobacterium radiobacter* strain K84 affords some protection against specific strains of *A. tumefaciens* (Moore, *Microbiol. Sci.* 5:92-95, 1988); however, gall disease remains a multimillion dollar worldwide problem. *Arabidopsis thaliana* plants resistant to gall disease have been produced by a traditional genetic approach (Nam et al., *Plant Cell* 9:317-333, 1997), but this strategy currently is not applicable to plants in which gall is a problem.

This invention is directed towards a new, more effective method of producing plants that are substantially resistant to gall disease caused by bacteria.

SUMMARY OF THE INVENTION

The present invention provides compositions that can be used to prevent tumor (gall) formation in plants infected with bacterial pathogens such as *Agrobacterium tumefaciens* and other species of *Agrobacterium*. These compositions comprise nucleic acid molecules that, when introduced into plants, can produce transgenic plants having enhanced resistance to tumors caused by such pathogens. The invention also encompasses transgenic plants that contain these nucleic acid molecules.

In general terms, the invention involves the use of nucleic acid constructs that encode untranslatable single-stranded RNA, double-stranded RNA, and/or untranslatable double-stranded RNA molecules that share specified high levels of sequence identity with target genes in the bacterial pathogen. For example, the

5 constructs may encode one or more types of untranslatable RNA molecules sharing high levels of sequence identity with one or more of the *iaaM*, *iaaH*, or *ipt* tumor genes of *Agrobacterium*. The invention also provides nucleic acid constructs that encode multiple different untranslatable single-stranded RNA, double-stranded RNA, and/or untranslatable double-stranded RNA molecules, including both sense

10 and antisense RNA molecules. For example, one construct provided by the invention encodes untranslatable RNA forms of both the *ipt* and *iaaM* genes of *Agrobacterium tumefaciens*; this construct can suppress both shooty and necrotic gall formation in plants caused by a pathogenic strain of *A. tumefaciens* infecting the plant.

15 The untranslatable RNA molecules appear to inhibit gall formation by triggering sequence-specific destruction of RNA molecules encoded by certain "target genes" of the infecting pathogen in the plant. However, the mechanism by which this occurs is not fully understood. For optimal efficacy, the untranslatable single-stranded RNA, double-stranded RNA, and/or untranslatable double-stranded

20 RNA molecules should be of a sufficient length and share a minimum degree of sequence identity with the target bacterial gene such that disease resistance is conferred to the host cell. The level of disease resistance conferred to the host cell by the RNA molecule can be determined using the experiments described below. Thus, the RNA molecules encoded by the constructs provided herein are typically at

25 least 25 nucleotides in length and share at least 60% sequence identity with the target gene of the pathogen. However, enhanced tumor suppression may be obtained by increasing the length of the untranslatable single-stranded RNA, double-stranded RNA, and/or untranslatable double-stranded RNA molecules (e.g., to at least 100, or at least 200 nucleotides) and/or by enhancing the level of sequence identity with the

30 target gene (e.g., to at least 70%, 75%, 80%, or 90% sequence identity).

04434837.110499

The invention also provides transgenic plants containing one or more of the above-described nucleic acid constructs. These constructs may be introduced into any plant species, but commercial crop plants for which *Agrobacterium* is a significant pathogen are expected to be particularly benefited by this technology.

The invention also provides chimeric plants that include both untransformed cells and transformed cells. These plants display "conferred resistance" in that the transgenic portion confers disease resistance to the non-transgenic portion. The chimeric plants are particularly useful for generating resistant, but not transgenic, fruits and other consumable portions of plants that are not transgenic.

SEQUENCE LISTINGS

The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three-letter code for amino acids. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.

SEQ ID NO: 1 is a primer used to produce the mutant *iaaM* gene.

SEQ ID NO: 2 is a primer used to produce the mutant *iaaM* gene.

SEQ ID NO: 3 is a primer used to produce the mutant *ipt* gene.

SEQ ID NO: 4 is a primer used to produce the mutant *ipt* gene.

SEQ ID NO: 5 is the DNA sequence that encodes an untranslatable RNA molecule having a high sequence identity with the *Agrobacterium ipt* gene.

SEQ ID NO: 6 is an amino acid sequence that is encoded by the untranslatable RNA molecule depicted in SEQ ID NO: 5.

SEQ ID NO: 7 is a DNA sequence encoding the untranslatable RNA molecule having a high sequence identity with the *Agrobacterium iaaM* gene.

SEQ ID NO: 8 is an amino acid sequence encoded by the untranslatable RNA molecule depicted in SEQ ID NO: 7.

SEQ ID NO: 9 is the nucleic acid sequence of the *ipt/iaaM* untranslatable construct.

SEQ ID NO: 10 is the nucleic acid sequence of the *iaaM* gene.

SEQ ID NO: 11 is the nucleic acid sequence of the *iaaH* gene.

SEQ ID NO: 12 is the nucleic acid sequence of the *ipt* gene.

DESCRIPTION OF DRAWINGS

Figure 1 is a diagram of the *A. tumefaciens* transferred DNA ("T-DNA") that contains three oncogenes: *iaaM*, *iaaH*, and *ipt*. Triangles represent T-DNA border sequences which delimit T-DNA ends by initiating and terminating T-DNA transfer (Peralta and Ream *Proc. Natl. Acad. Sci.* **82**:5112-5116, 1985). Arrows show direction and length of messenger RNAs (mRNAs) produced in gall tumors.

Figure 2 is a diagram of the auxin and cytokinin biosynthetic pathways encoded by the *A. tumefaciens* T-DNA oncogenes.

Figure 3 is a diagram of the binary plant transformation vector (pPEV6) (panel A) and of mutant transgenes that can be used to elicit co-suppression of DNA oncogenes. "RB" and "LB" denote right and left T-DNA border sequences, respectively. NOS prom/NPTII denotes the nopaline synthase promoter fused to the neomycin phosphotransferase II gene (conferring kanamycin resistance). 5' UTR and 3' UTR denote the 5' and 3' untranslated regions, respectively, associated with the cauliflower mosaic virus promoter (CaMV 35S Pro). Arrowheads denote respective restriction sites for *Xba*I, *Bam*HI, and *Eco*RI; numbers indicate respective coordinates relative to the vector sequence. Premature stop codons are shown in bold, whereas natural start codons are shown in plain text.

Figure 4 illustrates the most likely scenario for the creation of double-stranded RNA. The sense strand is transcribed from the CaMV 35S promoter and the anti-sense strand is transcribed from the NOS promoter.

Figures 5(A)-5(F) depict several representative illustrations of bacterial-resistance constructs (BR construct) according to the invention. Promoters are designated by the capital letter "P" and the direction of expression is denoted by respective arrows. DNA sequences encoding untranslatable RNA molecules that target specific genes are indicated; however, one of ordinary skill in the relevant art

will appreciate that untranslatable RNA molecules targeting other genes can be substituted. **Figure 5(A)** shows a BR construct in which one promoter (designated P₁) is used to express (direction of expression is indicated by the arrows) a DNA sequence encoding the sense-strand of a sequence that targets the *ipt* gene and the sense-strand of a sequence targeting the *iaaM* gene. This same construct also contains a second promoter (designated P₂) that drives the expression of the antisense-strand of the *iaaM* gene and the antisense-strand of the *ipt* gene. Thus, the combination of both promoters will generate a double-stranded RNA that contains a section targeting the *ipt* gene and a section targeting the *iaaM* gene. **Figure 5(B)** shows a BR construct that contains one promoter (P₁) that expresses a DNA sequence encoding several different untranslatable RNA sequences that target both the *ipt* gene and the *iaaM* gene. Starting at the 5' end of the construct, the promoter P₁ drives the expression of a sense-strand targeting the *ipt* gene, a sense-strand targeting the *iaaM* gene, an antisense-strand targeting the *iaaM* gene, and a sense-strand targeting the *ipt* gene. This sequence can fold back on itself, and thus generate a double-stranded RNA molecule comprising regions homologous to both the *ipt* and *iaaM* gene. **Figure 5(C)** shows another variation of a BR construct. This construct comprises independent promoters, P₁ and P₂, to drive the expression of an untranslatable RNA molecule in both the sense and anti-sense orientations, respectively. Two additional promoters (P₃ and P₄) are utilized for the expression of the sense and anti-sense expression of a second untranslatable RNA. **Figure 5(D)** shows another variation of the BR construct. This construct comprises one promoter (P₁) to express first the sense-strand and then the antisense-strand of an untranslatable RNA molecule targeting the *ipt* gene. This construct also comprises a second promoter to express both the sense-strand and antisense-strand of an untranslatable RNA targeting the *iaaM* gene. **Figures 5(E) and 5(F)** illustrate additional variations that can be used to express single-stranded untranslatable RNA molecules.

DETAILED DESCRIPTION

I. Definitions and Abbreviations:

Untranslatable RNA molecule: An RNA molecule, either single-stranded or double-stranded, that is based on a naturally occurring RNA molecule but which, as a result of genetic manipulation, is incapable of being translated to yield the full-length protein encoded by its naturally occurring counterpart. For example, such RNA can be rendered untranslatable through the introduction of one or more premature termination codons (TAA, TAG, or TGA), or by introduction of a mutation that shifts the reading frame. Alternatively, for example, the RNA may be rendered untranslatable by the deletion of the AUG translation-initiation codon, or of the AAUAAA polyadenylation signal. The RNA may also be rendered untranslatable by simply removing a portion of the cDNA encoding the full-length protein. Thus, even if the sequence were translated, it would produce a truncated version of its naturally occurring counterpart.

Antisense-strand RNA: An RNA molecule that is complementary to a messenger RNA (which represents a corresponding "sense" strand).

Disease-resistant transgenic plant: A "disease-resistant transgenic plant" as used herein is a transgenic plant exhibiting more resistance to gall disease than a corresponding non-transgenic plant.

Operably linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence whenever the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous.

Recombinant: A recombinant nucleic acid is one having a sequence that is not naturally occurring in the organism in which it is expressed, or has a sequence made by an artificial combination of two otherwise-separated, shorter sequences. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g.,

by genetic engineering techniques. "Recombinant" is also used to describe nucleic acid molecules that have been artificially manipulated, but that contain the same control sequences and coding regions that are found in the organism from which the gene was isolated.

- 5 **Sense-strand RNA:** An RNA molecule that can serve directly as messenger RNA, i.e., that can be translated by ribosomes.

- Double-stranded RNA:** A "double-stranded RNA" is an RNA molecule that contains at least a 25-bp sequence including both a sense-strand and an antisense-strand. Double-stranded RNA molecules are additionally characterized by
10 the level of complementarity between the sense-strand and the antisense-strand. Complementarity refers to the amount of base pairing between the two sequences. For example, the sequence 5'-AUCGGAUAGU-3' is 100% complementary to the sequence 5'-ACUAUCCGAU-3' and 70% complementary to the sequence 5'-GAAAUCCGAU-3'. The double-stranded RNA should be of a sufficient length and
15 have a sufficient level of complementarity such that it confers disease resistance to the host cell (disease resistance can be determined using the assays described below). For example, the double-stranded RNA may have as little as 60% complementarity. Generally, however, double-stranded RNA sequences will have at least 70%, 75%, 80%, or 90% complementarity.

- 20 **Vector:** A "vector" is a nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences, such as an origin of replication, that permit the vector to replicate in a host cell. A vector may also include one or more screenable markers, selectable markers, or reporter genes and other genetic elements known in the art.

- 25 **Sequence identity:** The similarity between two nucleic acid sequences or between two amino acid sequences is expressed in terms of the level of sequence identity shared between the sequences. Sequence identity is typically expressed in terms of percentage identity; the higher the percentage, the more similar the two sequences.

00434837-10493

Methods for aligning sequences for comparison purposes are well known in the art. Various programs and alignment algorithms are described in: Smith & Waterman, *Adv. Appl. Math.* **2**:482, 1981; Needleman & Wunsch, *J. Mol. Biol.* **48**:443, 1970; Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* **85**:2444-2448, 1988; Higgins and Sharp, *Gene* **73**:237-244, 1988; Higgins and Sharp, *CABIOS* **5**:151-153, 1989; Corpet et al., *Nucleic Acids Research* **16**:10881-10890, 1988; Huang, et al., *Computer Applications in the Biosciences* **8**:155-165, 1992; and Pearson et al., *Methods in Molecular Biology* **24**:307-331, 1994. Altschul et al., *J. Mol. Biol.*, **215**:403-410, 1990, presents a detailed consideration of sequence alignment methods and homology calculations.

The NCBI Basic Local Alignment Search Tool (BLAST™, Altschul et al., *J. Mol. Biol.*, **215**:403-410, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the Internet, for use in connection with the sequence-analysis programs blastp, blastn, blastx, tblastn and tblastx. BLAST™ can be accessed at <http://www.ncbi.nlm.nih.gov/BLAST/>. A description of how to determine sequence identity using this program is available at http://www.ncbi.nlm.nih.gov/BLAST/blast_help.html.

For comparisons of amino acid sequences of greater than about 30 amino acids, the "Blast 2 sequences" function in the BLAST™ program is employed using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per-residue gap cost of 1). When aligning short peptides (fewer than about 30 amino acids), the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins having even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 45%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% sequence identity.

A first nucleic acid is "substantially similar" to a second nucleic acid if, when optimally aligned (with appropriate nucleotide insertions or deletions) with the other

nucleic acid (or its complementary strand), nucleotide sequence identity occurs in at least about 60%, 75%, 80%, 85%, 90% or 95% of the nucleotide bases (As used herein, "optimally aligned" sequences exhibit a maximal possible sequence identity).

Sequence similarity can be determined by comparing the nucleotide sequences of

- 5 two nucleic acids using the BLAST™ sequence analysis software (blastn) available from The National Center for Biotechnology Information. Such comparisons may be made using the software set to default settings (expect = 10, filter = default, descriptions = 500 pairwise, alignments = 500, alignment view = standard, gap existence cost = 11, per residue existence = 1, per residue gap cost = 0.85).

- 10 Similarly, a first polypeptide is substantially similar to a second polypeptide if it shows sequence identity of at least about 75%-90% or greater when optimally aligned and compared using BLAST™ software (blastp) using default settings.

Bacterial resistance construct (BR construct): A "bacterial resistance construct" (abbreviated "BR construct") is a sequence of DNA that incorporates at

- 15 least one promoter and at least one DNA sequence encoding an untranslatable RNA (either double-stranded RNA, single-stranded RNA or a combination thereof). The arrangement of the promoter(s) in relationship to the DNA sequence(s) can vary. Representative configurations are illustrated in **Figures 5(A)-5(G)**. **Figure 5(A)**

shows a BR construct in which one promoter (designated P₁) is used to express

- 20 (direction of expression is indicated by the arrows) a DNA sequence encoding the sense-strand of a sequence that targets the *ipt* gene and the sense-strand of a sequence targeting the *iaaM* gene. This same construct also contains a second promoter (designated P₂) that drives the expression of the antisense-strand of the *iaaM* gene and the antisense-strand of the *ipt* gene. Thus, the combination of both

- 25 promoters will generate a double-stranded RNA that contains a section targeting the *ipt* gene and a section targeting the *iaaM* gene. **Figure 5(B)** shows a construct that contains one promoter (P₁) that expresses a DNA sequence that encodes several different untranslatable RNA sequences targeting both the *ipt* gene and the *iaaM*

gene. Starting at the 5' end of the construct, the promoter P₁ drives the expression of

- 30 a sense-strand targeting the *ipt* gene, a sense-strand targeting the *iaaM* gene, an

09434637.110499

antisense-strand targeting the *iaaM* gene, and a sense-strand targeting the *ipt* gene.

This sequence can fold back on itself, and thus generate a double-stranded RNA molecule comprising regions homologous to both the *ipt* and *iaaM* gene. **Figure 5(C)** shows another variation of a BR construct. This construct comprises

- 5 independent promoters, P₁ and P₂, to drive the expression of an untranslatable RNA molecule in both the sense and anti-sense orientations, respectively. Two additional promoters (P₃ and P₄) are utilized for the expression of the sense and anti-sense strands of a second untranslatable RNA. **Figure 5(D)** shows another variation of the BR construct. This construct comprises one promoter (P₁) to express first the sense-strand and then the antisense-strand of an untranslatable RNA molecule targeting the *ipt* gene. This construct also comprises a second promoter to express both the sense-strand and antisense-strand of an untranslatable RNA targeting the *iaaM* gene.
- 10

- Figures 5(E) and 5(F)** illustrate additional variations that can be used to express single-stranded untranslatable RNA molecules. **Figures 5(A)-(F)** are intended to illustrate a few of various different promoter/DNA sequence combinations that are possible. A person of ordinary skill in the art will appreciate that many additional combinations can be used in BR constructs according to the invention.
- 15

II. General Description

- 20 The present method provides new and effective methods for suppressing the expression of *Agrobacterium* oncogenes. In particular, this invention is directed at, *inter alia*, producing plants that are capable of substantially inhibiting the formation of bacterially induced galls. These plants are produced by selecting a target gene of *Agrobacterium* origin, designing a nucleic acid (typically DNA) BR construct
- 25 encoding untranslatable single-stranded RNA, double-stranded RNA, and/or untranslatable double-stranded RNA molecules having a high sequence identity to the target gene, and introducing at least one of these BR constructs into a host cell.

09434837-130499

a. Selection of the Target Gene

There are many species of *Agrobacterium*, for example *Agrobacterium tumefaciens*, *Agrobacterium vitis*, *Agrobacterium rubi*, and *Agrobacterium rhizogenes*. The nucleic acid sequences of the respective oncogenes contained within these species are highly conserved. Therefore, a BR construct designed to encode at least one RNA molecule having high sequence identity to one or more target tumor-inducing *Agrobacterium* genes will likely confer resistance to at least one (typically multiple) species of *Agrobacterium*.

b. Producing a Nucleic Acid Construct Encoding an Untranslatable RNA

Practicing the present invention requires the manipulation of a DNA sequence using molecular biological techniques to produce the desired nucleic acid construct. The DNA sequence can be manipulated using standard procedures such as restriction enzyme digestion, fill-in with DNA polymerase, deletion by exonuclease, extension by terminal deoxynucleotide transferase, ligation of synthetic or cloned DNA sequences, site-directed sequence-alteration via single-stranded bacteriophage intermediate or with the use of specific oligonucleotides in combination with PCR. Details of these techniques are provided in standard laboratory manuals such as Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y., 1989, and Ausubel et al., *Short Protocols in Molecular Biology*, 2nd ed., John Wiley and Sons, 1992.

Suppression of an oncogene using a method according to this invention is achieved by expressing, in a host cell, molecules of a BR construct having high sequence identity to the target gene(s). At least one molecule of the BR construct having substantial sequence identity to the target gene(s) is introduced into a host cell. The BR construct can be delivered into the host cell genome by delivering into the host a vector cell containing the BR construct.

Application of the present invention to construction of a BR construct desirably involves the selection of appropriate control sequences such as promoters,

enhancers, and 3'-untranslated regions. The choice of which type of control sequence(s) to use in a BR construct will depend upon the particular tissue in which the BR construct will be expressed and the particular sequence(s) of the target gene(s). The variety of plant that is selected for transformation will also affect the choice of the control sequence(s), the vector, and the transformation method.

Constructing a suitable BR construct involves the selection of a DNA sequence that will be used to target at least one specific bacterial gene. Generally, the DNA sequence will encode an untranslatable RNA having at least 70% sequence identity with the target bacterial gene(s) (i.e., the gene(s) that will be suppressed).

In producing the BR construct, a DNA molecule homologous to a target bacterial gene can be manipulated to render a single-stranded RNA or double-stranded RNA molecule encoded by the DNA molecule untranslatable. This can be done by, e.g., introducing any of various stop signals into the open reading frame of the DNA molecule to produce the BR construct. For example, the BR construct can be configured to contain one or more premature stop codons. A "stop codon" is a codon of the genetic code that signals ribosomes to terminate translation of a messenger RNA molecule. There are three stop codons in the genetic code: TAA, TAG, and TGA, as illustrated in Table 1 below.

TABLE 1
The Genetic Code

	First Position	Second position				Third Position
5	(5' end)	T	C	A	G	(3' end)
	T	Phe	Ser	Tyr	Cys	T
		Phe	Ser	Tyr	Cys	C
		Leu	Ser	STOP (och)	STOP	A
10		Leu	Ser	STOP (amb)	Trp	G
	C	Leu	Pro	His	Arg	T
		Leu	Pro	His	Arg	C
		Leu	Pro	Gln	Arg	A
		Leu	Pro	Gln	Arg	G
15	A	Ile	Thr	Asn	Ser	T
		Ile	Thr	Asn	Ser	C
		Ile	Thr	Lys	Arg	A
		Met	Thr	Lys	Arg	G
	G	Val	Ala	Asp	Gly	T
20		Val	Ala	Asp	Gly	C
		Val	Ala	Glu	Gly	A
		Val (Met)	Ala	Glu	Gly	G

- 25 In the context of the foregoing discussion, a "premature" stop codon is located at a position transcriptionally upstream of a naturally occurring stop codon. Generally, the premature stop codon is positioned within 100 nucleotides of the translation-start codon, and typically within 50 nucleotides of the translation-start codon.

- 30 One or more stop codons can be inserted into the DNA sequence to produce the BR construct. Alternatively, the DNA sequence can be mutated to convert an

existing triplet codon (encoding an amino acid) of the sequence into a stop codon.

For example, the hypothetical DNA sequence:

... CTT AAC TGG TCC ...

would normally produce a corresponding RNA translated by ribosomes to produce the polypeptide:

... Leu Asn Trp Ser ...

The corresponding RNA can be rendered untranslatable by introducing a stop codon, such as TAA, into the DNA sequence. For example, the modified DNA sequence:

... CTT TAA AAC TGG TCC ...

encodes:

... Leu STOP

Alternatively, in the foregoing hypothetical DNA sequence, substitution of the ninth nucleotide (guanosine (G)) by adenosine (A) will result in the creation of a premature stop codon, rendering the corresponding RNA untranslatable, i.e., the following DNA sequence is produced:

... CTT AAC TGA TCC ...

which encodes:

... Leu Asn STOP

Alternatively, the addition or deletion of one or more bases into or from, respectively, the DNA sequence (except multiples of three bases) can be used to displace the reading frame of the DNA sequence which can render the corresponding RNA molecule untranslatable. For example, the introduction of a single nucleotide

(G) into the first codon of the foregoing hypothetical DNA sequence creates a new reading frame containing a premature stop codon:

... CTG TAA CTG GTC C ...

5 which encodes:

... Leu STOP

10 An alternative manner of rendering an RNA molecule untranslatable is to remove the translation-initiation codon (usually ATG) from the corresponding DNA sequence. However, this method may result in use by ribosomes of an ATG codon elsewhere in the DNA sequence to initiate translation. Removal of the initiation codon ATG is, therefore, desirably used in conjunction with inserting one or more

15 premature stop codons into a DNA sequence.

Another method of introducing a premature stop codon is by truncating the subject DNA sequence. This can be done, for example, by using a restriction enzyme to excise a portion of a target gene and then cloning only the excised portion of the gene into a vector. Transcription of the vector will produce a segment of

20 homologous RNA effective to produce a co-suppression phenomenon, but will not produce a fully processed protein. Currently, the mechanism by which co-suppression works is not known. However, the phenomenon has been previously described in detail (Lindbo and Dougherty, *Virology* **189**:725-733, 1992).

One or more of the above approaches may be used to render an RNA

25 molecule encoded by a BR construct untranslatable. It will be appreciated that a very large number of sequence changes can be made in a suitable manner, the precise nature of which may depend on the actual DNA sequence being manipulated, to render the sequence of the corresponding RNA untranslatable. In certain embodiments, more than one stop codon may be introduced into the DNA sequence.

30 For example, the resulting BR construct may contain a DNA sequence encoding untranslatable RNA that has been altered to contain at least one stop codon situated early in the open reading frame; the open reading frame is thus "truncated."

0443837 110199

Many standard DNA mutagenesis techniques are available to modify DNA sequences in a manner as described above to produce the BR construct. The mutagenesis techniques include, for example, M13 primer mutagenesis. Details of such techniques are provided in Sambrook et al., Chapter 15, *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y., 1989; and in Ausubel et al., Chapter 8, *Short Protocols in Molecular Biology*, 2nd ed., John Wiley and Sons, 1992.

According to another aspect of the invention, double-stranded RNA molecules are provided that are homologous to a target bacterial gene. Each strand of the double-stranded RNA can be produced from separate BR constructs, wherein a first BR construct encodes the antisense-strand and a second BR construct encodes the sense-strand. Upon transcription of the first and second BR constructs, the resulting sense-strand and corresponding antisense-strand form double-stranded RNA.

Alternatively, the sense-strand and antisense-strand can be produced from a single BR construct. The single BR construct can utilize two distinct promoters to initiate the expression of the antisense-strand and the sense-strand, or one promoter to drive expression of both strands. When a single promoter is utilized, both the sense-strand and the antisense-strand are normally produced as a single transcript, wherein the RNA sequence will fold back on itself to create a double-stranded RNA. Similarly, multiple combinations of promoters, antisense-strands, and sense-strands can be encoded on the same BR construct.

Double-stranded RNA can also be produced by transforming cells with a BR construct that encodes the sense-strand, a self-cleaving ribozyme, and the antisense-strand all on a single transcript. Upon transcription of such a BR construct, the sense-strand, the self-cleaving ribozyme, and the antisense-strand are produced. The self-cleaving ribozyme sequence folds back on the resulting transcript and splices the transcript between the sense- and antisense-strands, generating two independent complementary strands of RNA.

A proposed mechanism for suppressing a target bacterial gene by introducing into a host cell molecules of a BR construct having one or more sequences homologous to at least a portion of the target gene typically involves the activity of an inducible, cellular activity that degrades specific RNA sequences. This mechanism requires that the untranslatable single-stranded RNA, double-stranded RNA, and/or untranslatable double-stranded RNA encoded by the BR construct be recognizable by the RNA-specific cellular activity. To such end, the target DNA sequence and the DNA sequence of the BR construct desirably share a sequence identity.

In the Examples presented below, the DNA sequences of the respective BR constructs are derived directly from corresponding target bacterial nucleotide sequences. The sequences of the respective BR constructs differ from the corresponding target sequences primarily only by the presence (in the sequences of the BR constructs) of premature stop codons inserted by mutagenesis involving one or more frame-shift mutations. Thus, in these examples, the BR constructs have over 90% sequence identity to the corresponding target DNA sequences. However, a BR construct needs only to have sufficient sequence identity to the target gene so that the BR construct confers disease resistance to the host cell. Therefore, a BR construct that encodes an RNA molecule having less than 90% sequence identity to the corresponding target DNA sequence can be used. In any event, the BR construct typically has at least 60% sequence identity to the corresponding target DNA molecule, and in some cases at least 70%, 75%, or 80% sequence identity to the target DNA molecule.

The following examples also describe BR constructs in which the DNA sequence corresponds to 700 base pairs of the ORF (open reading frame) of the target gene. It will be understood, however, that the untranslatable RNA provided by the BR construct need not correspond specifically to 700 base pairs of the ORF of the target gene; substantially shorter sequences of untranslatable RNA may also be effective.

09434837, 1104433

The BR construct should be sufficiently long and share a sufficient level of sequence identity to the target gene such that the BR construct confers disease resistance to the host cell. The ability of a particular BR construct to confer disease resistance to a host cell can readily be determined by using the assay described below, in which a transgenic plant is challenged with a bacterial pathogen. Typically, the ORF of the DNA sequence of the BR construct is at least 25-100 nucleotides in length, although longer sequences, such as 100-250, 250-500, or greater than 500 nucleotides may be used and may provide superior results. In embodiments where shorter sequences (i.e., less than 250 nucleotides) are utilized, the respective BR constructs will likely share a high degree of sequence identity (e.g., at least 60% sequence identity) with the target gene sequence.

The present invention can be used to suppress the expression of a bacterial tumor gene in a plant cell. To such end, the plant cell is transformed with a BR construct having a high sequence identity to a target bacterial gene. The molecule of the BR construct encodes one or more untranslatable single-stranded RNA and/or double-stranded RNA molecules. The BR construct can comprise a sequence of at least 25 nucleotides in length having at least 60% sequence identity to the target bacterial gene. Alternatively, the BR construct can comprise a sequence of at least 100 nucleotides in length having at least 60% sequence identity to the target bacterial gene. Furthermore, the BR construct can comprise a nucleic acid sequence of at least 250 nucleotides in length having at least 60% sequence identity to the target bacterial gene.

The present invention is not limited to the suppression of a single target bacterial gene. Rather, it is possible to suppress, according to the invention, the expression of multiple target genes using one or more BR constructs that comprise DNA sequences corresponding to several respective genes expressed in the target cell. This approach can be used to enhance resistance to a single bacterial strain or to produce resistance to multiple strains of bacteria in a single plant. As illustrated in the Examples below, the formation of a gall on a plant by a pathogenic bacterium infecting the plant can be reduced or eliminated by the introduction into the cells of

the plant, a BR construct having a high sequence identity to at least one gene of the infecting bacterium. This approach allows the production of transgenic plants resistant to the bacterium.

5 c. **Vectors**

It will be appreciated that the efficacy of the present invention depends on transcription of the DNA sequence of the BR construct introduced into a host plant cell. Transcription of a DNA sequence into messenger RNA is preferably effected by including a promoter region at the 5' end of the DNA sequence of the BR
10 construct, together with regulatory sequences at the 3' end of the DNA sequence. Many promoter sequences and 3'-regulatory sequences have been identified and characterized in a wide range of viral, bacterial, fungal, plant, and animal genes. Therefore, the selection of suitable promoter and a suitable 3'-regulatory sequence is within the capability of a person of ordinary skill in the relevant art.

15 After choosing and incorporating the appropriate regulatory DNA sequence(s) into the BR construct, the BR construct is incorporated into a suitable vector for introduction into the host cell. The choice of regulatory sequences, as well as the choice of a suitable transformation vector will depend upon the type of host cell into which the BR construct is to be introduced and upon the desired
20 transformation method for the host cell. Vectors suitable for transforming plant cells (derived from either monocotyledonous or dicotyledonous plants) are described below. Transformation of both monocotyledonous and dicotyledonous plant cells is now routine and the selection of the most appropriate transformation technique will be determined by the skilled practitioner.

25 A number of promoters that are active in plant cells have been described in the literature. Promoters that are known to cause transcription of DNA in plant cells can be used to suppress gene expression in plants. Such promoters can be obtained from plant cells or from plant viruses and include, but are not limited to, the CaMV (cauliflower mosaic virus) 35S promoter. It is desirable that the chosen promoter be
30 capable of causing sufficient expression of the BR construct to produce sufficient

RNA to suppress expression of the target gene. The amount of RNA needed to suppress expression of a particular target gene may vary from one target gene to another, expression level of the particular target gene, and the plant type.

Accordingly, whereas the CaMV promoter is employed in the Examples presented below, it will be understood that this promoter may not be optimal for all embodiments of the present invention.

The vector can be configured to optimally exploit the promoter and termination sequences in the target gene itself. Used in this way, the target-gene promoter is not altered and the subsequent stop signals are introduced into the ORF of the target gene. Additionally, the termination signals of the target gene can be left intact. This configuration permits increasing the transcription of untranslatable RNA and/or double-stranded RNA whenever the factors necessary for transcription of the target gene are present.

The promoter(s) used in a BR construct according to the invention may be modified, if desired, to include additional regulatory sequence(s). Such additional regulatory sequences can confer, e.g., specificity to the respective promoter region. For example, the small subunit of the ribulose bis-phosphate carboxylase ("ss RUBISCO") gene is expressed in plant leaves but not in root tissues. A sequence motif that represses the expression of the ss RUBISCO gene in the absence of light (to create a promoter which is active in leaves but not in root tissue), has been identified. This and/or other regulatory sequences such as the HSP70 leader sequence from petunia, may be ligated to promoters such as the CaMV 35S, or figwort mosaic virus (FMV) promoter, to modify the expression patterns of a gene.

The 3'-nontranslated region (that functions as a polyadenylation site for RNA in plant cells) of a gene can also be used in the present invention. Such 3'-non-translated regions include, but are not limited to, the 3'-transcribed (but non-translated) region of the CaMV 35S gene, the pea-rbcS E9 3'-non-translated region, the NOS 3'-non-translated region, and one or more of the 3'-transcribed, non-translated (but non-translated) regions containing the polyadenylation signals of the

tumor-inducing (Ti) genes of *Agrobacterium*, such as the tumor morphology large (*tml*) gene.

d. Plant Species

- 5 Gall formation in plants can be induced by any of various organisms. For example, galls can be induced by bacteria from the genus *Agrobacterium*, and certain species of *Pseudomonas*, *Rhizobacter*, and *Rhodococcus*.

- In the case of *Agrobacterium*, gall formation is caused by genes introduced into the plant cells on the Ti plasmid provided by an infecting bacterium.
- 10 There are a variety of naturally occurring Ti plasmids that can give rise to different types of galls. Galls are normally caused by *A. tumefaciens* which infects over 391 genera of plants including shrubs, fruit trees, nut trees, tuber-producing plants, conifers, grape vines, chrysanthemums, roses, cane berries, nursery crops, and commercially important plants (Bradbury, J.F. Guide to Pathogenic Bacteria. CAB
- 15 International, Slough, Britain, 1986). Hairy root is another type of gall induced by *A. rhizogenes*, that primarily affects the roots of apple trees. Finally, *Agrobacterium rubi* can infect both raspberries and black berries, and give rise to cane galls. (Agrios, *Plant Pathology*, Academic Press, 1997).

20 e. Transformation

- A BR construct according to the present invention is introduced into a plant cell using a suitable vector and transformation method as described below. The resulting transformed cells can then be allowed to regenerate into whole plants. Any of various conventional methods employed for transforming plant cells to generate
- 25 transgenic plants, including stably transformed plants, can be used in this invention. The choice of method will typically vary with the type of plant to be transformed; persons skilled in the art will recognize the suitability of particular methods for given plant types. Suitable methods may include, but are not limited to: electroporation of plant protoplasts; liposome mediated transformation; polyethylene
- 30 glycol-mediated transformation; transformation using viruses; microinjection of

plant cells; microprojectile bombardment of plant cells and *Agrobacterium tumefaciens* (AT)-mediated transformation. The DNA sequences comprising the CaMV 35S promoter and CaMV 35S non-translated 3' region and the mutated cDNA encoding a untranslatable RNA can be combined in a single cloning vector.

- 5 This vector can be transformed subsequently into, e.g., cultured tobacco cells.

f. Conferred Resistance

- The mechanism of co-suppression is unknown. However, transgenic tissue containing a co-suppression gene can be grafted onto a non-transgenic plant. The graft then confers resistance to the non-transgenic plant (Jorgensen et al., *Science*, 10 **279**:1486-87, 1998). Furthermore, this "conferred resistance" can be established by either grafting a scion (upper vegetative tissue) onto a transgenic stock (lower vegetative tissue), or by grafting a transgenic scion onto a non-transgenic stock. This conferred resistance can be transmitted through at least 30 cm of non-transgenic 15 tissue.

- It is possible that the phenomenon of conferred resistance may allow resistance to gall formation to be introduced into existing plants. Thus, a mature plant can be made resistant to gall formation by grafting transgenic tissue onto the plant. Furthermore, several grafts can be placed independently on the plant to 20 produce resistance in the plant to several different bacterial pathogens.

- A grafting protocol can be made more flexible by utilizing cross-species grafting. Thus, a graft from, e.g., almond (*Prunus amygdalus*) can be placed on stock from peach (*Prunus persica*). Such flexibility increases the range of plants for which a given transgenic tissue can be used. For example, after almond tissue 25 containing the desired BR construct has been generated, the tissue can be used to confer resistance not only to other almond trees, but also to peach trees.

The use of conferred resistance also decreases the possibility that a transgene made according to the invention will be introduced into the environment. This is because the resistance is derived from the graft itself and the rest of the plant

0944637.110139

remains free of the transgene. Therefore, the fruits and seeds of the plant can be left non-transgenic, so as not to transmit the gene.

By preventing a transgene from being systemically introduced into the plant, products for human consumption can be produced by the plant that are not transgenic.

III. EXAMPLES

a. Construction of BR Constructs Encoding Untranslatable RNA molecules

To produce a DNA construct capable of eliciting co-suppression, the *iaaM* and *ipt* oncogenes were modified by changing the third codon of each gene to a stop codon and introducing a frameshift mutation downstream of each respective introduced stop codon, thereby creating additional stop codons in the reading frame (Figure 3). The polymerase chain reaction (PCR) primer oligonucleotides used to create these mutations in the DNA construct are described in Table 2. The primers used to modify the *ipt* gene resulted in the deletion of the 5' C of the third codon and changed the 3' G of the third codon to an A. The *iaaM* modifications introduced the stop sequence TGA at the third codon and the two bases following the third codon were deleted. A second DNA construct was made that contained a hybrid transgene configured to elicit co-suppression of both *ipt* and *iaaM*. The second DNA construct was made by digesting a vector (containing the *ipt*-stop mutation) and a vector containing the *iaaM*-stop mutation with *Bam*HI. The fragment containing the *iaaM*-stop mutation was then ligated into the fragment containing the *ipt*-stop mutation, thereby yielding a BR construct containing the mutant *iaaM* gene inserted into the mutant *ipt* gene (Figure 3). The sequence of each DNA construct was verified, and the BR construct was inserted into a plant-transformation vector (pPEV6; Lindbo and Dougherty, *Mol. Plant-Microbe Interact.* 5:144-153, 1992) oriented such that the sense-strand of each mutant was expressed from the cauliflower mosaic virus (CaMV 35S) promoter (Figure 3).

Table 2PCR Primers Used to Produce Mutant *iaaM* and *ipt* Genes

Primers		Sequence
5	<i>iaaM</i> stop 5' primer	5'-CGGGATCCATGTCATGAACCTCTCCTTGA TAAC-3' (SEQ ID NO: 1)
	3' primer	5'-CGGGATCCTGCGACTCATAGT-3' (SEQ ID NO: 2)
15	<i>ipt</i> stop 5' primer	5'-GAAGATCTGATCATGGACTGAATCTAAT TTTCGGTCC-3' (SEQ ID NO: 3)
	3' primer	5'-GAAGATCTGATCACTAATACATTCCGAAC GG-3' (SEQ ID NO: 4)

**b. Construction of Double-Stranded RNA and Untranslatable
Double-Stranded RNA Vectors**

A vector encoding an *iaaM*-stop mutation (i.e., a DNA construct modified to incorporate a stop codon at the third codon, followed by a two base pair deletion) exhibited evidence of bacterial resistance. This resistance was derived from the production of double-stranded RNA by transcription of the vector (**Figure 4**). The sense-strand of the double-stranded RNA was transcribed from the CaMV 35S promoter and the antisense-strand was probably transcribed from the nopaline synthase promoter (NOS). Thus, this vector can produce a long double-stranded RNA that is approximately 2,000 bp long. Evidence of such a double-stranded RNA was found in northern blots that showed partially degraded antisense-strands ranging in size from 3.4 Kb to less than 0.24 Kb. As is depicted in Figure 4, the double-stranded RNA appeared to include an approximately 2,000 bp long region that was 100% homologous to the *iaaM* sequence. Therefore, bacterial resistance observed in *iaaM*-transgenic plants is probably attributable to the presence of the double-

stranded RNA. This resistance does not appear to have been due solely to the presence of the introduced stop codon.

Double-stranded RNA is capable of suppressing endogenous plant genes, as well as suppressing viral infection (Ruiz et al., *Plant Cell* 10:937-946, 1998).

- 5 However, the suppression, via double-stranded RNA and/or untranslatable RNA, of disease symptoms caused by bacteria, such as *Agrobacterium*, has previously not been shown.

c. Production of Plants Homozygous for Untranslatable RNA Transgenes

- 10 Mutant *iaaM* (SEQ ID NO: 7), *ipt* (SEQ ID NO: 5), and *ipt/iaaM* genes (SEQ ID NO: 9) were introduced separately into haploid tobacco (*N. tabacum*, "Burley" and "Kentucky" cultivars). The chromosomes of kanamycin-resistant transformants of these plants were doubled to produce plants homozygous for each transgene. These plants were the subjects of initial tests, which were repeated on the
- 15 F1 progeny of self pollinations.

d. Gall-resistant Plant Phenotypes

- Putative *iaaM*-suppressing plants (designated "TDP1" lines) were challenged with *ipt*-mutant *A. tumefaciens* (strain 338; Garfinkel et al., *Cell* 27:143-153, 1981).
- 20 Of 63 lines tested, 35 lines, including TDP1-B7 & TDP1-B17, suppressed the wild-type *iaaM* gene on *A. tumefaciens* T-DNA introduced into such plants, thereby preventing tumorous growth in the respective plants. When inoculated with wild-type *A. tumefaciens* (strain A348; Garfinkel et al., *Cell* 27:143-153, 1981), each of the 35 lines produced "shooty" galls typical of cytokinin-driven tumors, such as
- 25 those induced on wild-type plants inoculated with *iaaM*-mutant *A. tumefaciens* (Ream et al., *Proc. Natl. Acad. Sci. USA* 80:1660-1664, 1983; and Garfinkel et al., *Cell* 27:143-153, 1981). Thus, the plants that produced shooty galls exhibited the phenotype expected of a transgenic plant capable of suppressing *iaaM*.

- Putative *ipt*-suppressing plants (designated "CW1" lines) were challenged
- 30 with *iaaM*-mutant *A. tumefaciens* (strain 328; Garfinkel et al., *Cell* 27:143-153,

1981). Of 45 lines investigated, one (designated "CW1-K27") clearly suppressed the wild-type *ipt* gene on introduced *A. tumefaciens* T-DNA. Another 6 lines exhibited similar results in initial tests on the original transgenic plants, but these lines were lost before seeds were obtained. The *ipt*-suppressing plant (CW1-K27), when inoculated with wild-type *A. tumefaciens*, produced small necrotic galls typical of auxin-driven tumors, such as those induced on wild-type plants inoculated with *ipt*-mutant *A. tumefaciens* (Ream et al., *Proc. Natl. Acad. Sci. USA* **80**:1660-1664, 1983; Garfinkel et al., *Cell* **27**:143-153, 1981). There were 30 lines tested (designated "CW4" lines) that contained the hybrid *ipt-iaaM* transgene. One line (designated "CW4-B30") exhibited a significant reduction in tumorigenesis when inoculated with either wild-type, *iaaM*-mutant, or *ipt*-mutant *A. tumefaciens*. Although the CW4-B30 line exhibited markedly reduced gall size and absence of gall formation at some inoculation sites, gall tumorigenesis was not entirely absent. The controls were kanamycin-resistant plant lines (designated "PEV6" lines) that contained the transformation vector T-DNA (from pPEV6) without a transgene located downstream of the CaMV 35S promoter. As expected, none of these lines exhibited any suppression of T-DNA oncogenes upon infection with *A. tumefaciens*.

e. Molecular Analysis of Transgenic Plants

To examine transgene copy number and structural integrity, Southern blot analyses were performed on representative plant lines of each type. Most lines contained several copies of the transgene, and all lines contained one or more intact copies (see Tables 3, 4, and 5, below). Some lines also contained rearranged copies of the transgene, which were identified by the presence of multiple bands in the Southern blots.

TABLE 3
Southern Blot of Genomic DNA Digested with *Bam*H1

Transgenic Plant	1799-bp Transgene Fragment (+/-)*	Oncogene Suppression (+/-)*
CW4 B1 (ipt-stop/iaaM-stop)	+	-
CW4 B11 (ipt-stop/iaaM-stop)	+	-
CW4 B22 (ipt-stop/iaaM-stop)	+	-
CW4 B30 (ipt-stop/iaaM-stop)	+	+/-
TDP1 B7 (iaaM-stop)	+	+
TDP1 B17 (iaaM-stop)	+	+
TDP1 B27 (iaaM-stop)	+	+
TDP1 B31 (iaaM-stop)	+	-
PEV6 B2 (vector alone)	-	-
PEV6 B14 (vector alone)	-	-
* + denotes the presence of the transgene fragment or the suppression of oncogene expression. - denotes the absence of the transgene fragment or the absence of oncogene expression.		

5

TABLE 4
Southern Blot of Genomic DNA Digested with *Eco*R1

Transgenic Plant	Transgene Copy Number	Oncogene Suppression (+/-)*
TDP1 B7 (iaaM-stop)	3-4	+
CW4 B1 (ipt-stop/iaaM-stop)	2	-
CW4 B11 (ipt-stop/iaaM-stop)	2	-
CW4 B22 (ipt-stop/iaaM-stop)	2	-
CW4 B30 (ipt-stop/iaaM-stop)	4	+/-
TDP1 B17 (iaaM-stop)	2	+
TDP1 B27 (iaaM-stop)	1	+
TDP1 B31 (iaaM-stop)	4<	-
PEV6 B2 (vector alone)	0	-
PEV6 B14 (vector alone)	0	-
* + denotes the presence of the transgene fragment or the suppression of oncogene expression. - denotes the absence of the transgene fragment or the absence of oncogene expression.		

10

TABLE 5
Southern Blot of Genomic DNA Digested with
either *HinfI* or *EcoRI* Digested Genomic DNA

Transgenic Plant	Presence of Restriction Fragment (+/-)*	Restriction Enzyme	Suppression of Oncogenes (+/-)*
CW1 K27 (ipt-stop)	+	<i>HinfI</i>	+
CW1 K27 (ipt-stop)	+	<i>EcoRI</i>	+
CW1 K52 (ipt-stop)	+	<i>HinfI</i>	-
CW1 K52 (ipt-stop)	+	<i>EcoRI</i>	-
* + denotes the presence of the transgene fragment or the suppression of oncogene expression. - denotes the absence of the transgene fragment or the absence of oncogene expression.			

5

The foregoing results show that co-suppression drastically reduces accumulation of mRNA encoded by the eliciting transgene and mRNA encoded by other genes that contain sufficient (approximately 70% or more) sequence similarity (Marano and Baulcombe, *Plant J.* 13:537-546, 1998). Hence, Northern blot analysis was used to measure mRNA accumulation (but not transcription rate). In all *iaaM*-suppressing lines that were examined, transgene mRNA was undetectable, as expected, using a strand-specific hybridization probe. However, full-length and degraded antisense RNA molecules that included the transgene sequences were detected using a double-stranded hybridization probe. These transcripts appear to have initiated from the vector's nopaline synthase promoter and continued through both the neomycin phosphotransferase gene (in the sense direction) and the *iaaM* transgene (in the antisense direction). In the successful *ipt*-suppressing line, a trace amount of transgene-encoded mRNA was detected. Another line that contained the *ipt* transgene accumulated a large amount of transgene mRNA, but this line failed to co-suppress an incoming *A. tumefaciens* T-DNA-borne *ipt* gene. Plants that contained the hybrid *ipt-iaaM* transgene accumulated varying quantities of transgene-encoded mRNA. As expected, most of these lines did not elicit any co-suppression and only one line elicited partial co-suppression.

20

f. Discussion

By studying the ability of wild-type and *iaaM*- or *ipt*-mutant *A. tumefaciens* to induce tumors on various lines of transgenic plants, it has been shown that: 1) many lines suppressed an incoming T-DNA *iaaM* gene, 2) one line suppressed an incoming T-DNA *ipt* gene, and 3) one line partially suppressed both *ipt* and *iaaM* genes simultaneously.

By combining successful *iaaH*- or *iaaM*-suppressing transgenes with an *ipt*-suppressing transgene in a single plant line, a transgenic plant fully resistant to gall formation can be produced. This can be done through standard breeding techniques, in which a cross between lines homozygous for the individual genes is performed. The F2 generation will include plants homozygous for both transgenes; such plants are expected to substantially resistant to gall formation. This expectation is supported by data from a plant that contained the hybrid *ipt-iaaM* transgene. This plant nearly prevented gall formation, indicating that a single hybrid gene can elicit co-suppression against two target oncogenes.

The transgenes used in this study will likely elicit co-suppression against a broad variety of *Agrobacterium* species, as well as various strains of such species. This allows the production of plants (such as grape vines, fruit trees, nut trees, and chrysanthemums) that are resistant to gall formation. Other studies have established that approximately 70% sequence identity is required to elicit co-suppression (Marano and Baulcombe, *Plant J.* **13**:537-546, 1998). Fortunately, the target T-DNA oncogenes (*iaaM* and *ipt*) are highly conserved among diverse *A. tumefaciens* strains. Even limited-host-range grape-specific *A. vitis* strains have greater than 90% sequence identity with the octopine-type oncogenes used in our study (Otten and DeRuffray, *Mol. Gen. Genet.* **245**:493-505, 1994).

Having illustrated and described the principles of the invention in multiple embodiments and examples, it should be apparent to those skilled in the art that the invention can be modified in arrangement and detail without departing from such principles. Therefore, the invention encompasses all modifications coming within the spirit and scope of the following claims.

Claims:

1. A method of producing a plant cell that is resistant to gall disease, the method comprising transforming a plant cell with at least one nucleic acid molecule that is homologous to at least one gene responsible for causing gall disease, the nucleic acid molecule encoding an RNA molecule selected from the group consisting of untranslatable plus-sense RNA molecules, double-stranded RNA molecules, and untranslatable double-stranded RNA molecules.
2. The method of claim 1, wherein the nucleic acid molecule contains at least one sequence that is homologous to at least one gene selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and fragments thereof.
3. A plant-transformation vector, comprising the nucleic acid molecule of claim 2.
4. A plant cell transformed with the plant-transformation vector of claim 3.
5. A differentiated plant, comprising plant cells produced according to the method of claim 1.
6. A method of producing a plant exhibiting a reduced susceptibility to gall disease caused by *Agrobacterium*, comprising:
transforming at least one plant cell with at least one nucleic acid molecule that is homologous to at least one gene responsible for causing gall disease, or fragment thereof, the nucleic acid molecule encoding an RNA molecule selected from the group consisting of untranslatable plus-sense RNA molecules,

double-stranded RNA molecules, and untranslatable double-stranded RNA molecules;

growing plants from the transformed plant cells; and

selecting a plant that shows a reduced susceptibility to gall disease

5 caused by *Agrobacterium*.

7. A plant exhibiting a reduced susceptibility to disease caused by *Agrobacterium*, produced by the method of claim 6.

10 8. A chimeric plant, comprising at least one non-transformed plant cell grafted to the plant of claim 7.

9. A plant produced by sexual or asexual reproduction of the plant of claim 7.
15

10. A seed produced by selfing or outcrossing the plant of claim 7.

11. A recombinant nucleic acid molecule comprising a nucleic acid sequence having at least 60% sequence identity with a nucleic acid sequence selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and fragments thereof, the recombinant nucleic acid molecule, when introduced into and expressed in a plant, reduces susceptibility of the plant to disease caused by *Agrobacterium*.
20

25 12. A vector, comprising the recombinant nucleic acid molecule of claim 11.

13. A transgenic plant cell transformed with the vector of claim 12.

14. A transgenic plant, comprising at least one transgenic cell transformed with a recombinant nucleic acid molecule, as recited in claim 13.
30

09:43:48.37.110499

15. The transgenic plant of claim 14, wherein the plant is selected from the group consisting of apricot, blackberry, pear, peach, plum, blueberry, cherry, kiwi, quince, raspberry, and rose.

16. A chimeric plant, comprising at least one transgenic plant cell as recited in claim 13.

17. A BR construct.

18. A composition, comprising the BR construct of claim 17.

19. An RNA transcribed from the BR construct of claim 17.

20. A vector, comprising the BR construct of claim 17.

21. A plant cell transformed with the vector of claim 20.

22. A plant, comprising at least one plant cell according to claim 21.

23. A method of producing a plant cell that is resistant to gall disease, the method comprising:

providing a BR construct;

introducing the BR construct into a plant cell; and

assessing the level of gall resistance exhibited by the plant cell.

24. A plant, comprising at least one plant cell produced according to the method of claim 23.

25. The transgenic plant of claim 14, wherein the plant is
chrysanthemum.

26. The transgenic plant of claim 14, wherein the plant is selected from
5 the group consisting of conifers and poplars.

27. The transgenic plant of claim 14, wherein the plant is an ornamental
shrub.

10 28. The transgenic plant of claim 14, wherein the plant is selected from
the group consisting of almond, apple, grape, and walnut.

09474837 11049
64011 2842460

**PLANTS HAVING ENHANCED GALL RESISTANCE AND METHODS
AND COMPOSITIONS FOR PRODUCING SAME**

5

ABSTRACT

Methods and compositions for suppressing gall formation in plant cells induced by *Agrobacterium* infection are disclosed. The methods involve introducing at least one DNA construct, encoding at least one untranslatable sense-strand RNA and/or double-stranded RNA, into a plant cell. Introduction of these molecules into the plant cell causes the plant cells to become resistant to gall formation.

10

09434637-110459





Figure 1

09434837-110499



Figure 2

A. T-DNA of pPEV6 vector



B. TRANSGENE CONSTRUCT

TRANSGENIC
PLANT LINE

TDP1

iaaM stop

5'-ATGTCATGAACCTCTCCTTCGATAAC-3'

ipt stop

5'-CGTTCGGAATGTATTAGTG-3'

CW1

ipt stop/iaaM stop

CW4

Figure 3.

Figure 3




Figure 4




Figure 5

COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **PLANTS HAVING ENHANCED GALL RESISTANCE AND METHODS AND COMPOSITIONS FOR PRODUCING SAME**, the specification of which

☒ is attached hereto.

☐ was filed on _____ as Application No. _____.

☐ was described and claimed in PCT International Application No. _____, filed on _____, and as amended under PCT Article 19 on _____ (if applicable).

☐ and was amended on _____ (if applicable).

☐ with amendments through _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56. If this is a continuation-in-part application filed under the conditions specified in 35 U.S.C. § 120 which discloses and claims subject matter in addition to that disclosed in the prior copending application, I further acknowledge the duty to disclose material information as defined in 37 CFR § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT International application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)

Priority
Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐ ☐
Yes No

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

60/107,185

11-05-98

Application Number

Filing Date

09434837 110499

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT International filing date of this application:

(Application No.)_____
(Filing Date)_____
(Status: patented,
Pending, abandoned)

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from _____ as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application, to file a corresponding international application, and to transact all business in the Patent and Trademark Office connected therewith:

Name	Reg. No.	Name	Reg. No.
BEAN, Gregory V.	36,448	MAURER, Gregory L.	43,781
BECKER, Mark L.	31,325	MEYER, Joel R.	37,677
CALDWELL, Lisa M.	41,653	NOONAN, William D.	30,878
CAMPBELL, James	19,978	PETERSEN, David P.	28,106
DeGRANDIS, Paula A.	43,581	POLLEY, Richard J.	28,107
GEORGE, Samuel E.	44,119	SCOTTI, Robert F.	39,830
GIRARD, Michael P.	38,467	SIEGEL, Susan Alpert	43,121
JAKUBEK, Joseph T.	34,190	SLATER, Stacey C.	36,011
JOHNSON, Michelle L.	36,352	STEPHENS JR., Donald L.	34,022
JONES, Michael D.	41,879	STUART, John W.	24,540
KLARQUIST, Kenneth S.	16,445	VANDENBERG, John D.	31,312
KLITZKE II, Ramon A.	30,188	WHINSTON, Arthur L.	19,155
HARDING, Tanya M.	42,630	WIGHT, Stephen A.	37,759
LEIGH, James S.	20,434	WINN, Garth A.	33,220

Address all telephone calls to Paula A. DeGrandis at telephone number (503) 226-7391.

Address all correspondence to:

KLARQUIST SPARKMAN CAMPBELL
LEIGH & WHINSTON, LLP
One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, OR 97204-2988

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole or first Inventor: Wait Ream

Inventor's Signature _____ Date _____

Residence: Corvallis, Oregon

Citizenship: U.S.A.

Post Office Address: 6005 N.W. Vineyard Dr.
Corvallis OR 97330

Full Name of Second Joint Inventor, if any: Machteld Mok

Inventor's Signature _____ Date _____

Residence: Corvallis, Oregon

Citizenship: U.S.A.

Post Office Address: 3024 N.W. Garryanna Dr.
Corvallis OR 97330

Full Name of Third Joint Inventor, if any: Hyewon Lee

Inventor's Signature _____ Date _____

Residence: Pusan, Korea

Citizenship: South Korea

Post Office Address: 304-1002 Sunkyung 3 cha-APT
Guseo-2-Dong Gumjeong-Ku
Pusan, 609-312
KOREA

09434837.110499

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
In re application of:
Ream et al.

Art Unit: unassigned

Application No. new


CERTIFICATE OF MAILING

Filed: November 4, 1999

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on November 4, 1999 as First Class Mail in an envelope addressed to: BOX PATENT APPLICATION, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

For: PLANTS HAVING ENHANCED GALL
RESISTANCE AND METHODS AND
COMPOSITIONS FOR PRODUCING
SAME

Examiner: unassigned



Attorney for Applicant

Date: November 4, 1999

STATEMENT IN COMPLIANCE WITH 37 CFR § 1.821(f)


BOX PATENT APPLICATION
TO THE ASSISTANT COMMISSIONER FOR PATENTS
Washington, DC 20231

Sir:

In compliance with 37 CFR § 1.821(f), the undersigned declares that the nucleotide and amino acid sequences presented in the paper copy of the "Sequence Listing" submitted herewith are the same as the sequences contained in the computer-readable form of said "Sequence Listing."

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL
LEIGH & WHINSTON, LLP

By 

Paula A. DeGrandis
Registration No. 43,581

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

0943437 110499

SEQUENCE LISTING

<110> Ream, Walt et al.,

<120> Plants Having Enhanced Gall Resistance and
Methods and Compositions for Producing the Same

<130> 53629

<140>

<141>

<150> 60/107,185

<151> 1998-11-05

<160> 12

<170> PatentIn Ver. 2.0

<210> 1

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 1
cgggatccat gtcatgaacc ttccttgat aac 33

<210> 2

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 2
cgggatcctg cgactcata 19

<210> 3

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 3
gaagatctga tcattgactg aatctaattt tcggtcc 37

<210> 4

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 4

gaagatctga tcactaatc attccgaacg g

31

<210> 5
<211> 747
<212> DNA
<213> Agrobacterium tumefaciens

<400> 5
gaagatctga tcactgaact aatctaatTT tcggtccaac ttgcacagga aagacgacga 60
ccgcgatagc tcttgcccag cagacagggc ttccagtcct ttgcgttgat cgggtccaat 120
gctgtctcga acttaacac ggaagcggac gaccaacagt ggaagaaacga 180
cgctgtctcta ccttgatgat cggcctctgg ttgagggtat catcgagacc aagcaagctc 240
atcatagget gatcgaggag gtgtataatc atgaggccaa cggcgggctt attcttgagg 300
gaggatccac ctcggttgct aactgcatgg cgcgaacagc ctattggagt gcagattttc 360
gttgccatat tattgccac aagttaccgg accaagagac caggccattc tattattcaa gaggttggtt 480
ccagagttaa gcagatgttg caccocgctg caggccattc tattattcaa gaggttggtt 480
atctttggaa tgaacctcgg ctgaggccca ttctgaaaga gatcgatgga tatcgatag 540
ccatgttggt tgctagccag aaccagatca cgtcagatat gctattgcag cttgacgcaa 600
atatggaagg taagttgatt aatgggatcg ctacaggagta ttctatccat gcgcgccaa 660
aggaaacaga attccccaa gttacgcag cgcgtttcga cggattcgaa ggtcatccgt 720
tcggaatgta ttagtatga gatcttc 747

<210> 6
<211> 2
<212> PRT
<213> Agrobacterium tumefaciens

<400> 6
Met Asp
1

<210> 7
<211> 1807
<212> DNA
<213> Agrobacterium tumefaciens

<400> 7
cgggatccat gtcataaacc tctccttgat aaccagtcgc atcatctccc aacaaaaatg 60
gtggatctga caatggtcga taaggcggat gaattggacc gcagggttcc cgaatgccttc 120
ttagaacgag aagcttctag gggaaggagg attactcaaa gctccaccga gtgcagcgtc 180
gggttagctt gcataaaggct ggccgatggt cgcttccccg agatctcagc ttggtgaaag 240
gtagcagttc tctccgctta tatctatatt ggcaaaagaaa ttctggggcg gatacttgaa 300
tcgaaacctt gggcgccggc aacagtgaat ggtctcgttg ccacgcactt ggacaccatt 360
tgcatggatt tctccgaagc acaactaatc caagccctgt ttttgcctga cggtaaaaga 420
tgtgcacaga ttgatcttag tcatcttggt gccatttcaa tctctaagac tccggcgttt 480
cgaacccctgc caatgccgt gtacgagaat ggcacgatga aatgcgttac cgggtttaac 540
ataacccttg aaggggccgt gccatttgac atggtagctt atggtcgaaa cctgatgctg 600
aagggttcgg caggttcctt tccaaacatc gaettgctct acgaactgcag accgtttttt 660
gaccaatggt ccgatagtg accgatccgc ttctttccgg aggatgttcc taagcogaaa 720
gtggcggtca ttggcgctgg caattccgga ctggtgggtg caaacgaact gcttcgatct 780
ggggtagacg atgttacaat atatgaagca agtgatcgtg ttggaggcaa gctttggtca 840
catgctttca gggagcgtcc tagtgctcgt gcggaatgg gggcgatcgc atttctcctc 900
getgcattct gcttcttttt cttctccgag cgttaacggc tgtcttcgat gaggccgttc 960
ccaaatcccg gcacagtga cacttacttg gctaccaaag gcttccaata catgtggaaa 1020
gcggcgagc ttgccaccga gctgttccat cgcggtttca accggttggc ttgcgttctg 1080
aaggacggtt ttcatgagcg agatattgtg ttggtctcgc ctgtcgtat tactaagcc 1140
ttgaaatcag gaacattag gtgggctcat gactcctggc aattttggct gaacctgttc 1200
gggagggagt ccttctcttc agggatagag aggatcttcc ttgggcacaa tctcctcgtg 1260
ggtaaacatg gagttttctc catgattggg acctattcaa ataggatctg 1320
gcgggggttg gtccagtttt tgaagcggg ttatttgaga tctcccgctt ggtcatcaac 1380

```

ggatatgaag aaatcagcg gatgtgccct gaaggaatct cagaacttcc acgtcggtac 1440
gcattctgaag tggtaacagg tgtgtctgtg agccagcgca tatgcatagt tcaagtcagg 1500
gcatctcaga aggaagaagc aaaaataaag ataaggctta agagcgggat atctgaactt 1560
tatgataaag ttgtgtgtcac atctggactc gcaaatatcc aactcaggca ttgctgtaca 1620
tgcgatacca atatttttcca ggcaccagtg aaccaagcgg ttgataacag ccatatgaca 1680
ggatcgtcaa aactcttctc gatgactgaa cgaaaattct ggttagacca tatctccg 1740
tctgtgtccc tcatggacgg gatcgcaaaa gcagtgtatt gcctggacta tgagtcgcag 1800
gatcccg

```

```

<210> 8
<211> 2
<212> PRT
<213> Agrobacterium tumefaciens

```

```

<400> 8
Met Ser
1

```

```

<210> 9
<211> 2544
<212> DNA
<213> Agrobacterium tumefaciens

```

```

<400> 9
gaagatctga tcatggactg aatctaattt tcggtccaac ttgcacagga aagacgcaga 60
ccgcgatagc tcttgcacag cagacagggc ttccagtcct ttccgttgat cgggtccaat 120
gctgtctcca actatcaacc ggaagcggag gaccaacagt ggaagaactg aaaggaacga 180
cgctgtctcta ccttgatgat cggcctctggt tggagggtat catcgacgcc aagcaagctc 240
atcataggct gatcgaggag gtgtataatc atgaggccaa cggcgggctt attcttgagg 300
gaggtcccat gtcataaacc tctccttgat aaccagtgcg atcatctccc aaccaaagt 360
gtggtatctga caatggtcga taagcgggat gaattggacc gcagggtttc cgtatgcctc 420
ttagaacgag aagcttctag ggggaaggag attactcaaa gctccacaga gtgcagcgt 480
gggttagctt gcaaaaggct ggccgatggt cgcttccccg agatctcagg tgggtgaaag 540
gtagcagttc tctccgttta tatctataat ggcaagaata ttctggggcg gatactgaa 600
tcgaaacctt gggcgcgggc aacagtgagt ggtctcgttg ccatcgactt ggaacacctt 660
tgcattggat tctccgaagg acaactaatc caagcctgt ttttctgtag cggtaaaaga 720
tgtgcaccga ttgactctag tcatttctgt gccatttcaa tctctaagac tgcgcgctt 780
cgaaaccttc caatgccgct gtacaggaat ggcaagatga aatgcgttac cgggtttacc 840
ataaccttga aaggggcgct gccatttgac atggtagctt atggtcgaaa cctgatgctg 900
aagggttcggc caggtttcct tccaacaate gacttgcctc acgactgcag acggtttttt 960
gaccaatgtt ccgatatttg accgatcgcc tcttctccgg aggatgttcc aagccgaaa 1020
gtggcggtca ttggcgctg catctccgga ctggtggtgg caaacgaaat gcttcatgct 1080
ggggtagacg atgttacaat atatgaagca agtgatcgtg ttggaggcaa gctttgttca 1140
catgctttca gggacgctcc tagtgtcgtg gccgaaatgg gggcgatgag atttctctct 1200
gctgcaattc gcttgttttt ctctctcgag cggttacgccc tgtcttcggt gaggcgcttc 1260
ccaaatcccc gcacagtgca caacttactg gtctaccaag cgttccaata catgtgaaa 1320
acggggcagc tgcacagcaa gctgttccat cgcgtttaca acggttggtg ctgcttcttg 1380
gagcgcggtt ttcattgagc agatattgtg ttggtctcgc ctgtcgctat tactcaggcc 1440
ttgaaatcag gacacattat gtgggctcat gactcctggc aaatttggct gaaacggttt 1500
gggaggagat cctctctctc agggatagag aggatcttct tgggcacaga tctccttggt 1560
ggttaaacatg gagttttctc catgattggg acctattcaa gctaatggga ataggtatctg 1620
cggggttttg tccagatttt tgaaagcggg ttatttgaga tctcctcgct tcaagtcagg 1680
ggatatgaag aaatcagcg gatgtgccct gaaggaatct cagaacttcc acgtcggtac 1740
gcattctgaag tggtttaacgg tgtgtctgtg agccagcgca tatgcatagt tcaagtcagg 1800
tgatgataag ttgtgtgtcac atctggactc gcaaatatcc aactcaggca ttgctgtaca 1860
tgcgatacca atatttttcca ggcaccagtg aaccaagcgg ttgataacag ccatatgaca 1920
ggatcgtcaa aactcttctc gatgactgaa cgaaaattct ggttagacca tatctccg 1980
tctgtgtccc tcatggacgg gatcgcaaaa gcagtgtatt gcctggacta tgagtcgcag 2100
gatccacctc gttgtctaac tgcatggcg gaacacgata ttggagtcca gattttcgtt 2160

```

ggcatattat	tcgccacaag	ttaccgcacc	aagagacctt	catgaaagcg	gccaaaggcca	2220
gagttaaaga	gatgtgtcac	ccgcgtgcag	gccattctat	tattcaagag	ttgggtttatc	2280
tttgggaatga	acctcggtcg	aggcccatct	tgaagagat	cgatggatat	cgatatggcca	2340
tgttgtttgc	tagccagaac	cagatcacgg	cagatatgct	attgcagctt	gacgcaaatc	2400
tggaaaggtaa	gttgattaat	gggatcgctc	aggagtattt	catccatgcg	cgcccaacagg	2460
aacagaaatt	cccccagtt	aacgcagccg	ctttcgacgg	attcgaaggt	catccggttcg	2520
gaatgtatta	gtgatcagat	cttc				2544

<210> 10
 <211> 2268
 <212> DNA
 <213> Agrobacterium tumefaciens

<400> 10						
atgtcagctt	cacctctctt	tgataaccag	tgcatcacc	tcaccaacca	aatgggtgat	60
ctgacaatgg	tcgataaagg	ggatgaattg	gaccgcaggg	ttcccgatgc	ctttattgaa	120
cgagaagctt	ctagggggaag	gaggattact	caaaagctcca	ccgagtgacg	cgctggggtta	180
gcttgcaaaa	ggctgcgttc	tggtcgcttc	cccgagatct	cagctggtgg	aaaggttagca	240
gtctctcccg	cttatatcta	tattggcaaa	gaaattctcg	ggcggtatct	tgaattcgaaa	300
ctctggggcg	gggcaacagt	gagtggtctc	gttgccatcg	acttggacac	catttgcgatg	360
gatttctcgc	aagcacaact	aatccaagcc	ctgtttttgc	tgagcggtaa	aagattgtgca	420
ccgattgtatc	ttagtctatt	cgtggccatt	tcaattctcta	agactcgctg	ctttcgaaacc	480
ctgccaatgc	cgctgtacga	gaatggcagc	atgaattgcg	ttaccggggt	taccataacc	540
cttgaagggg	ccgtgcccatt	tgacattgta	gcttatggct	gaaacctgat	gctgaagggt	600
tcggcaggtt	ccctttccaac	aatcgacttg	ctctacagct	gcagacgggt	ttttgaccac	660
tgctccgata	gtggcaggat	cggtctcttt	ccggaggatg	ttcctaagcc	gaaagtggcg	720
gtcattggcg	ctggcatttc	cggactcgtg	gtggcaaacg	aactgcttca	tgctgggggta	780
gacgatgtta	caatatatga	agcaagtgat	cgtgttgagg	gcaagctttg	gtcacatgct	840
ttcaggagacg	ctctagtgct	cgtggccgaa	atggggcgca	tgcatatttc	ttctgtgtgca	900
ttctgcttct	ttttcttctc	cgagcggtac	ggcctgtctt	cgatgaggcg	gttccccaaat	960
cccggtcagtg	tcgacactta	cttggctctac	caagcgctcc	aatacattgtg	gaagcgcggtg	1020
cagctgccac	cgaagctggt	ccatcgcgtt	tacaacggtt	ggcgtgcggt	gttgaaggac	1080
ggtttctcat	agcgagatat	tgtgttggtc	tcgcctgtgc	ctattactca	ggccttgaaa	1140
tcaggacaca	ttaggtgggc	tcgatgctcc	tgccaaattt	ggctgaaccg	tttcggggag	1200
gagtcctctc	cttccagggat	agagaggatc	ttctcgggca	cacatctctc	tggtgtgttaa	1260
catggaggtt	ttctcatgat	tgggacctat	tcgaagctaat	gggaatagga	ttctggcggtg	1320
tttgggtccg	tttttgaaag	cggtgttatt	gagatctctc	gcttgggtcat	caacggatat	1380
gaagaaaatc	agcggtatgtg	ccctgaaggga	atctcagaac	ttccagctcg	gatcgcatct	1440
gaagtgggtta	acgggtgtgtc	tgtgagccag	cgcataatgcc	atgttccaagt	caggggcgatt	1500
cagaaggaaa	agacaaaat	aaagataaagg	cttaagagcg	ggatatctga	actttatgat	1560
aaagtggtgtg	tcacattctg	actcgcaaat	atccaactca	ggcatttcct	gacatcgcat	1620
accaaatatt	ttcaggcacc	agtgaaaccaa	cggtgttgata	acagccatgat	gacaggatcg	1680
tcaaaaactct	tcctgatgac	tgaacgaaaa	ttctggttag	accatatctc	cccgctcttg	1740
gtcctcatgg	acgggatcgc	aaaagcagtg	tattgcctgg	actatgagtc	gcaggatccg	1800
aatggtaaa	gtctagtgct	catcagttat	acatgggagg	acgaactccca	gaagctgttg	1860
cggtgtcccc	acaaaaaaga	gcgattatgt	ctgctcgggg	acgcaatttc	gagatctttc	1920
ccggcgtttg	cccgacacct	atttctctgc	tgctgtgatt	acgacaaaaa	tgattattcaa	1980
catgatgtgc	ttacagacga	gaatgcgggg	ggagctttca	aactcaacgc	cggtgggtgag	2040
gatttttatt	ctgaagaact	tttctttcaa	gcactggaca	cggttaattga	taccggagtt	2100
tacttgcggg	gttgcagttg	ttctctcaca	ggtggatggg	tgagggggtg	tattcagacc	2160
cggtgtaacg	cgctctgtgc	aattatccac	aattgtggag	gatttttggc	aaagggcaatt	2220
ctctctogac	actcttggaa	gagatataac	taccgcagta	gaaattag		2268

<210> 11
 <211> 1404
 <212> DNA
 <213> Agrobacterium tumefaciens

<400> 11						
atggtggcca	ttactctggt	agccccaaag	ctagaacacc	tgaacaggaa	agactactcc	60
tgcttagaac	tagtagaaac	tctgatagcg	cgtgtggaag	ctgcaaaatc	attaaacgcc	120

cttctggccta	cagactggga	tggtttgcg	cgaagcgcca	aaaaaattga	tcgccatgga	180
aacgcggag	taggtctttg	cgcattcca	ctctgtttta	aggcgaaacat	cgtaccggc	240
gtatttccca	caagcgccgc	taocgcggcg	ctgataaacc	acttgccaaa	gataccatcc	300
cgcgtgcag	aaagactttt	ttcagctgga	gcactgccgg	gtgcctcggg	aaatattgcat	360
gagttatcgt	ttgggaattac	aagcaacaac	tatgccaccg	ggggcggtg	aaaccgctg	420
aatccagatc	tgataccagg	gggctcaaac	gggtggtg	ctgcctcggt	agcaagccga	480
ttgatgttag	gcgcatagg	caccgatacc	gggtgatctg	ttcgctacc	cgcagccctg	540
tgtggcgctg	taggatttcg	accgacgctt	ggtagatatc	cgggagatcg	gataataaccg	600
gttagcccta	cccgggacac	tcccggaatc	atagcgagct	gcgtagccga	tgttgtaatc	660
ctcgaccgga	taatttccgg	cacacccggag	agaataccac	ccgtgcgcct	gaagggggcta	720
aggatcgcc	tccttacaac	ctacttttat	gatgaccttg	atgctgatgt	ggccctagca	780
gctgaacaa	cgattcgctc	gctagcaaac	aaaggcgtaa	cttttgtgtg	agctaacatt	840
ccccaaactg	cggacatgaa	taaaaggggc	agcttccag	tgcactcta	tgaatttcca	900
cacgctctaa	aacagtatct	cgacgacttt	gtaaaaactg	tttcttttct	tgacgtcatc	960
aaaggaattc	gtagccctga	tgtagccaac	attgccaatg	cgcaaatgga	tggacatcaa	1020
atttccaaag	ctgaatatga	actggcccg	cactccttca	gaccaagact	tcaagccacc	1080
tatcgcaact	acttcaaac	gaatagatta	gatgctattc	tcttcccaac	agcacccctg	1140
gtggccagac	ccataggcca	ggattcctca	gttatccaca	atggccagat	gctggacaca	1200
ttcaagatct	acgtgcgaaa	tgtggaacca	agcagcaacg	caggcctacc	tggcttgagc	1260
attcctgttt	gcctgacacc	tgatcgcttg	cctgttggaa	tggagatcga	tggattagcg	1320
gattcagacc	aacgtctgtt	agcaatcggg	ggggcatgtg	aaagaagccat	tggattccga	1380
tattttgccc	gtttacccaa	taa				1404

<210> 12
 <211> 723
 <212> DNA
 <213> *Agrobacterium tumefaciens*

<400> 12						
atggacctgc	atctaatttt	cgggtccaact	tgacacaggaa	agacgacgac	cgcgatagct	60
cttgccaccg	agacagggtc	tccagtcctt	tcgcttgatc	gggtccaact	ctgctcctca	120
ctatcaaccg	gaagcggagc	accaacagtg	gaagaactga	aaggaaacgac	cgctctctac	180
cttgatgac	ggcctctggg	ggagggtatc	atcgacgcca	agcaagctca	tcataggctg	240
atcgaggagg	tgtataatca	tgaggccaac	ggcgggctta	ttcttgaggg	aggatccacc	300
tcgttgctca	actgcatggc	gcgaacacgc	tattggagtg	cagattttcg	ttggcatatt	360
attcgccaca	agttaccgga	ccaagagacc	ttcatgaaag	cggccaaggc	cagagttaa	420
cagatgttgc	accccgctgc	aggccattct	attattcaag	agttggttta	tctttggaat	480
gaacctcgcc	tgaggcccat	tctgaaagag	atcgatggat	atcgatatgc	catgttgttt	540
gctagccaga	accagatcac	ggcagatatg	ctattgcagc	ttgacgcgaaa	tatggaaggt	600
aagttgatta	atgggatcgc	tcaggagtat	ttcatccatg	cgcgcgaaca	ggaacagaaa	660
ttcccccaag	ttaacgcagc	cgctttcgac	ggattcgaag	gtcatccggt	cggaaatgat	720
tag						723

CG444637.10463